NEUROPREMS cross-disciplinary project

Redefining the trajectories of neurodegenerative diseases at the presymptomatic stage

Neurodegenerative diseases are a major public health challenge, causing increasing disability, and there is a lack of curative treatments. NeuroPrems aims to identify high-risk individuals in the presymptomatic phase before symptoms appear. By characterizing degenerative biomarkers at this key stage, the project paves the way for new early, targeted therapeutic strategies.

OUR CHALLENGE

Characterizing degenerative and inflammatory profiles and their clinical links across nine diseases

The project will recruit 1,000 participants at Paris Brain Institute for long-term clinical assessments, imaging, and sleep analyses, and will enable the creation of a biobank.

PROJECT OBJECTIVES

1. Create a unique resource for studying the presymptomatic phase of neurodegenerative and inflammatory diseases by collecting clinical, imaging, neurophysiological, and biomarker data.
2. Identify biomarkers to define the spectrum, conversion, and progression of the disease.

MAJOR ADVANCES

The project has obtained all regulatory approvals and participant recruitment will begin shortly. It takes advantage of the unique environment offered by Pitié-Salpêtrière Hospital and Paris Brain Institute, which brings together expert centers for neurodegenerative diseases, national reference centers for rare diseases, research teams, and cutting-edge core facilities.